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Abstract 
Background: Regarding the antimonial-resistant of Leishmania spp., understanding of related mechanism is neces-
sary. One of the most important involved molecules is aquaglyceropin1 (AQP1). The aim of this study was molecu-
lar analysis of AQP1 gene from antimonial-resistant clinical isolates and its expression.  
Methods: Overall, 150 patients with cutaneous leishmaniasis referring to the reference laboratories of Yazd and 
Varzaneh,, located 105km southeast of Isfahan and 240km away from Yazd, were assessed from Jun 2015 to Dec 
2017. After sampling, staining was done and evaluated for Leishman by microscope. Samples were collected in 
RNAlater solution for gene expression analysis in non-healing isolates. DNA extraction was performed from each 
slide with Leishman body. All patients with L. major isolates detected by ITS1-PCR-RFLP were followed for find-
ing the resistant isolates, consequence of molecular characterization of AQP1 using PCR-RFLP. Gene expression of 
AQP1 from all resistant isolates was assessed in comparison with the one in a sensitive isolate. Statistical analysis 
was done using SPSS. The significance level was considered ≤0.05. 
Results: Five isolates were detected as antimonial resistant. Molecular detection and identification were appeared 
that all were L. major. The molecular characterization of AQP1 showed G562A mutation. Gene expression of AQP1 
in resistant isolates showed 1.67 fold higher than the sensitive isolate.  
Conclusion: We reported a new point mutation of G562A in AQP1 gene involved in molecular mechanism in re-
sistant isolates.  
 
Keywords: Leishmaniasis; Cutaneous; Drug rsesistance; Antimony  
 
Introduction 
 
Leishmaniasis, caused by Leishmania spp., 
is one of the most important parasitic diseas-
es which occurs in various forms including 
cutaneous (CL), muco-cutaneous, disseminat-
ed cutaneous, and visceral. CL is resulted from 
L. major and L. tropica in the Old World. The 
first line of treatment for CL is pentavalent an-
timony [Sb(V)] such as sodium stibogluconate 
(pentostam®) and meglumine antimonite (glu- 
 
 
cantime®) (1). One of the important clinical 
concerns for the treatment of various infec-
tious diseases especially CL is drug resistance. 
Resistance to antimonial drugs as the first line 
of treatment has been reported in leishmani-
asis in several countries (2-4). One of the im-
portant molecules involving antimonial re-
sistance is Aquaglyceroporin 1. This protein 
that encoded from AQP1 gene presented on 
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chromosome 31 has critical role in transport-
ing the antinomial drug inside the parasite and 
therefore any changes in its expression and 
gene sequence may involve in antimonial re-
sistance development (5, 6).   
Based on our knowledge, the presence of 
a point nucleotide mutation in the genes in-
volved in drug absorption comes into effect 
by interacting with the drug and the target or 
changing the permeability of the drug into the 
parasite (7). Three antimonial-resistant isolates 
had a deletion of 64 of 204kb base pairs at the 
end region of chromosome 31 (8). This dele-
tion is included parts of AQP1 gene. Another 
study found a nucleotide change in position 
of 398 in AQP1 gene from non-healing iso-
lates that resulted in changing the amino ac-
id glycine to aspartic acid that it seemed to 
affect the absorbance of antimonial (9). Re-
cently, we reported a new mutation of G562A 
in AQP1 gene from the standard isolate of L. 
major.  
For finding any correlation of this muta-
tion and molecular mechanism of antimonial 
resistance, in this study, we investigated the 
molecular characterization and gene expres-
sion of AQP1 in resistant isolates obtained from 
patients with CL. 
 
Materials and Methods 
 
Population study 
In this cross-sectional study, the research 
population included suspected cases of CL re-
ferring to the reference laboratories of two dif-
ferent endemic regions of Iran, including Yazd, 
located 270km (170mi) southeast of Isfahan, 
and Varzaneh, located 105km southeast of 
Isfahan and 240km away from Yazd, from 
Jun 2015 to Dec 2017.  
Totally, 150 patients were considered for 
assessing. All patients were followed at least 
for 3 months after treatment to finding the 
resistant isolates. 
The informed consent was completed from 
all patients included in this study. The ethi-
cal approval with the code of IR.SSU. MED-
ICINE.REC.1394.532 has been taken from 
the Research Ethics Committee of Shahid 
Sadoughi University of Medical Sciences, 
Yazd, Iran.  
 
Sampling 
After sterilizing, the edge of each lesion 
was sampled and placed on two separate 
slides. After preparing smear, it was fixed using 
methanol. The Giemsa staining was done. 
Then, Leishman body was screened using 
optical microscope. All positive samples were 
considered for the next steps. Moreover, sam-
ple of each patient was collected in RNAlater 
solution for gene expression of AQP1 in the 
non-healing clinical isolates in next steps. 
 
DNA extraction 
DNA extraction was done using DNA 
extraction kits (GeneAll, Tissue, and blood, 
Exgene cell SV, Korea, Seoul, #106-101) from 
the slides containing the parasite. The proto-
col was performed based on the company in-
struction by little modification. Each slide was 
washed by xylol. After drying, the samples 
of each slide scratched and transferred into a 
sterile 1.5ml microtube. The other steps were 
done based on the kit instructions.  
 
Detection and identification of species 
Since the target population was L. major 
isolates, the ITS1-PCR-RFLP was used to de-
tection and identification (10) using the spe-
cific primer pair of LITSR: 5′-CTGGATCA 
TTTTCCGATG-3′ and L5.8S: 5′-TGATA 
CCACTTATCGCACTT-3′. The amplification 
was done using thermocycler (ABI-SimpiAmp, 
USA). The presence of a fragment of 300–
320bp in length detected Leishmania spp. For 
identification, RFLP was done using Hae III 
restriction enzyme. The amplification and di-
gestion analysis were done by agarose gel 
electrophoresis alongside by 50bp DNA lad-
der. Fragments of 200 and 127bp in length 
after enzyme digestion, was considered as L. 
major. All patients with L. major isolates were 
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followed for three month for finding the re-
sistant ones.  
 
Molecular analysis of AQP1 
The non-healing clinical L. major isolates 
were included for G562A mutation analysis. 
The specific primer pair of LmAQP1-F: 5'-
TGTCTGGTGGTCACACTTGAAC-3' and 
LmAQP1-R: 5'-CACGACTAGAGGTATCC 
AAAAGTA-3' was used for AQP1 gene am-
plification. The amplification was done using 
thermocycler (ABI-SimpliAmp, USA). The 
reaction was done in a volume of 20µl con-
taining 10pmol each primer, 1U Taq DNA 
polymerase, 1X PCR buffer, 1.5mM MgCl2, 
0.2mM dNTP, and 100mg DNA as template. 
The reaction program included the first de-
naturation of 94 °C for 5min, followed by 40 
cycles of 94 °C for 1min, 56 °C for 1min, 
and 72 °C for 1min. The final extension was 
done at 72 °C for 5min. The amplicon size 
of 509bp in length showed the AQP1 am-
plification. Then, RFLP analysis was done 
with Zra I resctriction enzyme for G562A 
assessing. The pattern with the fragments of 
198 and 311bp in length was considered as 
wild type and no mutation but no digestion 
showed G562A mutation. Amplification and 
digestion analyses were done using agarose 
gel electrophoresis (1%) alongside with 50bp 
DNA ladder. 
 
Gene expression 
Total RNA from the non-healing clinical 
isolates was extracted using the GF-1 Total 
RNA Extraction Kit (Vivantis, Malaysia, #GF-
TR-025). The quality and quantity of the ex-
tracted RNA were done using 1% agarose gel 
electrophoresis and spectrophotometer (Ep-
pendorf BioPhotometer plus, Eppendorf, Ger-
many), respectively. The cDNA synthesis was 
performed using RevertAid™ First Strand 
cDNA Synthesis Kit (Thermo Fisher Scien-
tific, USA, K1621) based the protocol. All an-
timonial-resistant clinical isolates were as-
sessed in order to AQP1 gene expression using 
the specific primer pair of AQP1-F: 5ꞌ-
AGTGTGGAGCGAGGTGTTCAA-3ꞌ and 
AQP1-R: 5ꞌ-CCGAGAGTATGCGAGGTG 
ACAA-3ꞌ (2). A susceptible strain was con-
sidered as the standard one. The Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) 
gene was evaluated as the endogenous con-
trol with the specific primer pair of GAPDH-
F: 5ꞌ-CCGAGAGTATGCGAGGTGACAA-
3ꞌ and GAPDH-R: 5ꞌ-GCCCCACTCGTTGT 
CATACCA-3'. The amplification was done 
with thermocycler (Applied Biosystem step 
one; USA). The amplification was done in 
triplicate. The Real Time PCR program com-
prises the initial denaturation at 95 °C for 10 
min followed by 40 cycles of denaturation at 
95 °C for 10sec and annealing/extension at 60 
°C for 20sec. The specificity of amplification 
was performed by melting curves analysis. 
The analysis was performed using ∆∆Ct 
as (∆Ctsample-target-∆Ctsample-control)-(∆Ctstandard-
target-∆Ctstandard-control) and the Relative Quan-
titative (RQ) was calculated by 2-∆∆Ct. 
 
Statistical analysis 
Data were analyzed using SPSS-16 soft-
ware (Chicago, IL, USA). Chi-square test was 
used to compare qualitative variables. The 
significance level in the applied tests was ≤ 
0.05. 
 
Results 
 
Five age groups were classified. We clas-
sified the ages from 0 to 13 as group 1, 14 to 
20 as group 2, 21 to 40 as group 3, 41 to 50 
as group 4, and over than 50yr old as group 
5. Totally, 41 from group 1, 19 from group 
2, 65 from group 3, 18 from group 4, and 7 
from group 5 were included in this study. 
All isolates from groups 1 and 2 were suscep-
tible to treatment, while out of the isolates 
from group 3, three were non-healing and 62 
were susceptible to treatment. Among the iso-
lates from group 4, one was non-healing and 
17 were sensitive to treatment. Among the 
group 5, one was non-healing and six were 
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susceptible to treatment. Thus, the amount of 
K-square was measured as 5/28 with a sig-
nificant level of P= 0.260, and therefore the 
response to therapy and age group did not 
correlate with each other and act independent-
ly (Table 1).  
Out of 150 patients with CL, 84 were men 
and 66 were women. Out of 84 men, just one 
patient was resistant to treatment with anti-
mony and others were treated immediately 
after first prescription. Out of 66 women, four 
did not cure after three months considered as 
resistant to treatment. Totally, 5 isolates were 
non-healing. All non-healing isolates were re-
garding to Varzaneh. All isolates obtained from 
the patients with CL from Yazd were suscepti-
ble to antimonial drug.  
ITS1-RFLP-PCR was done for isolates. 
The results of PCR from the antimonial-re-
sistant clinical isolates showed an amplicon 
of around 3bp in length. Then, Hae III re-
striction enzyme analysis showed L. major 
pattern with the fragments of 200 and 100bp 
in length (Fig. 1).  
Molecular analysis of AQP1 sequencing 
for the mentioned mutation analysis showed 
all five isolates had G562A (Fig. 2).  
The mean RQ of AQP1 from the non-
healing clinical isolates showed 1.67 fold high-
er than the standard isolate as the sensitive 
one (Fig. 3). 
  
 
 
Fig. 1. Agarose gel electrophoresis for detection and 
identification of clinical isolates. ITS1-PCR-RFLP 
with the result of fragments with 100 and 200bp in 
length showed Leishmania major. Lane 1: 50bp DNA 
ladder, lane 2: standard L. major, lanes 3, 4: clinical 
isolates with the pattern of L. major after restriction 
analysis 
 
 
 
Fig. 2. Agarose gele electrophoresis for PCR-RFLP 
analysis for AQP1 gene in antimonial-resistant clini-
cal isolates. Lane 1: 50bp DNA ladder, lane 2: the 
fragment size of 509bp in length in positive control 
of Leishmania major after PCR-RFLP, no digestion 
showed G562A mutation; lanes 3–7: the fragment 
size of 509bp in length in five antimonial-resistant 
clinical isolates of L. major after PCR-RFLP, no di-
gestion showed G562A mutation, lane 8: the frag-
ment sizes of 198 and 311bp in length susceptible L. 
major isolate after PCR-RFLP 
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Fig. 3. Relative quantitative (RQ) of LmAQP1 in antimonial resistance clinical isolates of L. major by Real-Time 
PCR. Lm-S: The standard isolate, Lm1 to Lm5: the antimonial drug resistance clinical isolates 
 
Table 1. Correlation of the drug response and age category 
 
 :answer Treatment Total   
Non-
healing 
Sensitive 
Chi square P 
ID Group 1 
(0-13) 
Count 0 41 41 5.286 0.260 
% within answer 
Treatment 
0.0% 28.3% 27.3%  
Group 2 
(14-20) 
Count 0 19 19  
% within answer 
Treatment 
0.0% 13.1% 12.7%  
Group 3 
(21-40) 
Count 3 62 65  
% within answer 
Treatment 
60.0% 42.8% 43.3%  
Group 4 
(41-50) 
Count 1 17 18  
% within answer 
Treatment 
20.0% 11.7% 12.0%  
Group 5 (over than 
50 years old) 
Count 1 6 7  
% within answer 
Treatment 
20.0% 4.1% 4.7%  
Total Count 5 145 150  
% within answer 
Treatment 
100.0% 100.0% 100.0%  
 
Discussion 
 
We reported here the molecular charac-
terization of non-healing L. major clinical iso-
lates, including G562A mutation in LmAQP1  
 
 
and higher gene expression of LmAQP1 in 
comparison with the susceptible isolates. More-
over, the age and sex of the patients had not 
J Arthropod-Borne Dis, June 2019, 13(2): 145–152                                                    Y Alijani et al.: Molecular Analysis of … 
150 
 http://jad.tums.ac.ir 
Published Online: June 24, 2019 
any correlation with non-healing isolates. AQP1 
encodes the aquaglyceropin protein which is 
one of the important factors in antimony re-
sistant isolates (11). LmjAQP1 has critical 
roles in the parasite, including transporting 
solute such as water, glycerol, methylglyoxal, 
dihydroxyacetone, and sugar alcohols, regulat-
ing the volume, osmotaxis (12), and especially 
up taking of Sb (III). In this study, the muta-
tion of G562A in AQP1 makes the alteration 
of alanine to threonine. The gene expression 
of LmAQP1 in all non-healing isolates was 
1.67 fold more than the one in susceptible one. 
This mutation has especial role for increasing 
the LmAQP1 gene expression in this isolates.  
Gene expression regulation in Leishmania 
is controlled post-transcriptionally (13). Mito-
gen-Activated Protein Kinase (MPK) is the 
one of important key for control of AQP1 gene 
expression (14). Threonine is one of the im-
portant amino acid that could be the target of 
protein kinase for phosphorylation. The kinas-
es normally phosphorylated the OH group of 
threonine. In isolates studied in this study, 
G562A mutation was reported with substi-
tution of alanine by threonine. More phos-
phorylation of LmAQP1 make overexpression 
of the gene (14). Phosphorylation of threo-
nine in LmAQP1 stabilizes the protein and 
therefore increasing of the half-life of the 
AQP1 makes it overexpression. This overex-
pression resulted in more up taking the drug. 
Therefore, it is possible to arise a question 
which if this mutation could increase the sta-
bility of the protein and followed by overex-
pression, then why the isolates had the phe-
notype of non-healing. The answer reflects 
the facts that molecular mechanisms of an-
timonial resistant are multifactorial (15).  
Efllux of the drug (16) or inactivating the 
drugs or their metabolites are the other mech-
anisms that approved in the parasites (17). Alt-
hough the isolates in our study showed over-
expression of LmAQP1, after up taking the 
antimonial drugs, they may inactive or efflux 
from the parasite. Phosphorylation has not 
any effect on the channel activity but make 
stability (14). This stability makes amplified 
the other roles of the protein such as combat-
ing with osmotic stress. Based on knowledge, 
phosphorylation is dependent on oxidative 
stress presenting in environment, inside ei-
ther the vector body or mammalian macro-
phages (14). Therefore, LmAQP1 is phosphor-
ylated during the metacyclic stage to provide 
stability. This helps to parasite to combat os-
motic stress in metacyclic stage, the stage that 
is ready to infect the mammalian host.  
The role of MAP2 for phosphorylation of 
threonine for providing stability of LmAQP1 
and then overexpression needs more atten-
tion with the goal of developing a new ap-
proach for drug targeting. On the other hand, 
development of some compounds that target 
MAP2 for preventing phosphorylation and 
increasing the half-life of AQP1 may be dan-
gerous because MAP kinases in all organisms 
are familiar and therefore they might target the 
ones from human, too (18). Although AQP1 
protein belongs to the vast family of AQP in 
all organisms but finding some point nucleo-
tides inside it might be the better target for 
designing the drug. This strategy for decreas-
ing the stability of AQP1 effects on the other 
roles of this important protein such as com-
bating the osmotic stress. Consequence, de-
creasing the power of parasite for exposing 
to osmotic stress might be a powerful tool for 
control of the disease. One of the approaches 
for combating the non-healing isolates was 
induction of MPK2 in order to increase the 
stability of AQP1 in the non-healing isolates 
to force them more up taking of Sb (III) (14). 
Our results are not agreed with the hypothe-
sis of Mandal et al. (14) because the clinical 
non-healing isolates that we assessed in this 
study showed overexpression of AQP1 but 
they did not respond to antimonial therapy.  
The phenotypic characteristic in Leishma-
nia for providing susceptibility or resistance 
to drugs is multifactorial and therefore more 
investigations are necessary to find the mo-
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lecular mechanisms in detail by which Leish-
mania select. This is the first report of effec-
tive of G562A on AQP1 gene expression in 
clinical non-healing isolates. Moreover, pre-
senting a point mutation was reported inside 
AQP1 develops resistance isolate (7). G133D 
in AQP1 can be one of the mechanisms in 
non-healing isolates of Leishmania. Moreo-
ver, some other mutational analyses have been 
performed on LmAQP1 that revealed Ala163 
and Glu152 are involved in metalloid uptake 
and reduced permeability to antimony (19, 20). 
Therefore, in this study, we discovered the 
new resistance mechanism corresponding to 
a point mutation of AQP1. 
 
Conclusion 
 
The non-healing clinical isolates may have 
mutation of G562A in AQP1. This mutation 
can affect LmAQP1 gene expression. The mu-
tation of G562A resulted in providing addi-
tional threonine. Threonine may be the target 
of kinase enzyme for more stability of the 
AQP1 protein. Therefore, this alteration can 
be candidate for drug target. 
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